Oscotec Inc (039200) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Oscotec Inc (039200) has a cash flow conversion efficiency ratio of 0.263x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩48.00 Billion ≈ $32.53 Million USD) by net assets (₩182.53 Billion ≈ $123.70 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Oscotec Inc market capitalisation for the company's overall valuation and market capitalisation.
Oscotec Inc - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Oscotec Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Oscotec Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Oscotec Inc ranked by their cash flow conversion efficiency. Explore Oscotec Inc cash earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Invengo Information Technology Co Ltd
SHE:002161
|
0.016x |
|
Taiwan Semiconductor Co Ltd
TWO:5425
|
0.014x |
|
Interfor Corp
TO:IFP
|
0.068x |
|
Huachangda Intelligent Equipment Group Co Ltd
SHE:300278
|
0.035x |
|
Shanghai Yongmaotai Automotive Technology Co. Ltd.
SHG:605208
|
-0.025x |
|
Shanghai Pudong Road & Bridge Construction Co Ltd
SHG:600284
|
0.035x |
|
Kornit Digital Ltd
NASDAQ:KRNT
|
0.009x |
|
Beijing Water Business Doctor
SHE:300055
|
0.001x |
Annual Cash Flow Conversion Efficiency for Oscotec Inc (2011–2025)
The table below shows the annual cash flow conversion efficiency of Oscotec Inc from 2011 to 2025. View Oscotec Inc stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩186.85 Billion ≈ $126.62 Million |
₩8.30 Billion ≈ $5.63 Million |
0.044x | +122.59% |
| 2024-12-31 | ₩132.36 Billion ≈ $89.70 Million |
₩-26.03 Billion ≈ $-17.64 Million |
-0.197x | +15.50% |
| 2023-12-31 | ₩94.72 Billion ≈ $64.19 Million |
₩-22.05 Billion ≈ $-14.94 Million |
-0.233x | -7.93% |
| 2022-12-31 | ₩122.51 Billion ≈ $83.02 Million |
₩-26.42 Billion ≈ $-17.91 Million |
-0.216x | +29.04% |
| 2021-12-31 | ₩28.83 Billion ≈ $19.54 Million |
₩-8.76 Billion ≈ $-5.94 Million |
-0.304x | +9.83% |
| 2020-12-31 | ₩53.05 Billion ≈ $35.95 Million |
₩-17.88 Billion ≈ $-12.12 Million |
-0.337x | -63035.38% |
| 2019-12-31 | ₩51.29 Billion ≈ $34.76 Million |
₩27.47 Million ≈ $18.62K |
0.001x | +100.49% |
| 2018-12-31 | ₩46.29 Billion ≈ $31.37 Million |
₩-5.08 Billion ≈ $-3.44 Million |
-0.110x | +36.83% |
| 2017-12-31 | ₩21.24 Billion ≈ $14.40 Million |
₩-3.69 Billion ≈ $-2.50 Million |
-0.174x | +44.31% |
| 2016-12-31 | ₩26.33 Billion ≈ $17.84 Million |
₩-8.21 Billion ≈ $-5.56 Million |
-0.312x | -1397.65% |
| 2015-12-31 | ₩26.92 Billion ≈ $18.24 Million |
₩646.84 Million ≈ $438.35K |
0.024x | +126.68% |
| 2014-12-31 | ₩21.78 Billion ≈ $14.76 Million |
₩-1.96 Billion ≈ $-1.33 Million |
-0.090x | -166.09% |
| 2012-12-31 | ₩24.47 Billion ≈ $16.58 Million |
₩3.34 Billion ≈ $2.26 Million |
0.136x | +832.77% |
| 2011-12-31 | ₩25.73 Billion ≈ $17.43 Million |
₩375.90 Million ≈ $254.74K |
0.015x | -- |
About Oscotec Inc
Oscotec Inc. operates as a clinical stage drug discovery and development company. It develops SYK inhibitor that is in Phase IIa clinical trial to treat rheumatoid arthritis and immune thrombocytopenia; FLT3 inhibitor, which is in Phase I clinical trial for the treatment of acute myeloid leukemia; and EGFR double mutation inhibitor to treat non-small cell lung cancer, as well as Anti-Tau antibody… Read more